Vozvrashchenie altretamina v praktiku lecheniya bol'nykh s disseminirovannym i retsidivnym rakom yaichnikov
- Authors: Garin AM1, Stenina MB1, Tyulyandin SA1, Toloknov BO1, Zhordaniya KI1, Borisov VI2, Smirnova OD2, Voznyy EK3, Dobrovol'skaya NY.3, Bol'shakova SA3, Khvatova GI3
-
Affiliations:
- РОНЦ им. Н.Н. Блохина РАМН
- Московский городской онкологический диспансер
- РНЦРР
- Issue: Vol 2, No 4 (2000)
- Pages: 113-114
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26379
- ID: 26379
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
A M Garin
РОНЦ им. Н.Н. Блохина РАМН
M B Stenina
РОНЦ им. Н.Н. Блохина РАМН
S A Tyulyandin
РОНЦ им. Н.Н. Блохина РАМН
B O Toloknov
РОНЦ им. Н.Н. Блохина РАМН
K I Zhordaniya
РОНЦ им. Н.Н. Блохина РАМН
V I Borisov
Московский городской онкологический диспансер
O D Smirnova
Московский городской онкологический диспансер
E K Voznyy
РНЦРР
N Yu Dobrovol'skaya
РНЦРР
S A Bol'shakova
РНЦРР
G I Khvatova
РНЦРР
References
- Блохин Н.Н., Переводчикова Н.И. Химиотерапия опухолевых заболеваний. М.,1984; 200-13.
- Маренич А.Ф., Переводчикова Н.И., Григорова Т.М., Паскевичус Р.И. Сравнительное изучение двух режимов комбинированной химиотерапии при лечении больных раком яичников III и TV стадии. Вестн. АМН СССР, 1980; 5: 28-32.
- Foster В J. Role ofhexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack? Cane Treat Rep 1986; 70: 1003-101.
- Single agent chemotherapy in the management of ovarian carcinoma. In "Ovarian Cancer". Eds. Albert D., Surwit E., Boston 1985; 115-46.
- Rustin G., Nelstrop A.E., Crawford M., et.al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluating of defining response by Serum CA-125J Clin Oncol 1997; 15(1): 172-6.
- Marietta A, Tewari K., Podczaski E.S. Hexamethylmelamine as a single second - line agent in ovarian cancer: follow up report and review of the literature. Gyn Oncol 1997; 66:20-6.
- Vergote I, Himmelmann A, Frankendal В., et al. Hexamethylamine as second - line therapy inplatin resistant ovarian cancer. Gyn Oncol 1992; 47: 282-6.
- Moore D.H, Valea V, Grumpier L.S., Fowler W.C Hexamethylamine/altretamine as second line therapy for epithelial ovarian carcinoma. Gyn Oncol 1993; 51: 109-12.
- Schinkf C, Harris L.S., Grosen E.R., Bailey H.H. Altretamine an effective salvage chemotherapy after paclitaxel in women with recurrent platinum resistant ovarian cancer. Proc. ASCO 1995; ah. 2 75-
- Kristensen G.B., Balkelandt M., Vergote I.B., Trope С A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Eurf Cane 1995; 31 A(11): 1778-80.
- Frasci G, Cornelia G, Cornelia P., etal. Carboplatin - hexamethylmelamine - oral etoposide first - line treatment of ovarian cancer patients with bulky disease: a phase II study. Gyn Oncol 1995; 58: 68-73.
- Hainsworth J.D., Jones III H.W., Burnett L.S., et al. The role ofhexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison ofhexamethylmelamine, cyclophosphamide, doxorubicine and cisplatin versus cyclophosphamide, doxorubicin and cisplatin. Amerf Clin Oncol 1998; 13(5): 4Ю-5.
- Edmonson J.H., Mc Cormack G.W., Wleand H.S. Late emerging survival differences in a comparative study of HCAP vs CP in stage III-L.V ovarian carcinoma. Adjuv Ther Cane 1990; 6:512-21.
- Greenberg A.C, Kudelka A.P., Kavanagh J. Ovarian cancer. In 'Medical Oncology A comprehensive review" Ed Pazdur R., 1993; 235-420